Johnson & Johnson and Novavax Seek Emergency Approval in India

Strategic Insights -

The Indian government is poised to receive emergency approvals for COVID-19 vaccines developed by Johnson & Johnson (J&J) and Novavax. The two companies, which have partnered with Indian manufacturers, have submitted applications to the Drugs Controller General of India (DCGI). J&J's single-dose vaccine has been approved in several Western countries, while Novavax's dose has shown promising results in clinical trials, with an efficacy rate of 90%. The development comes as India attempts to stave off a third wave of COVID-19.

Key Takeaways:

  • Johnson & Johnson (J&J) and Novavax have applied for emergency approval of their COVID-19 vaccines in India, raising the possibility of large quantities of doses becoming available.
  • J&J's single-dose vaccine has been approved in several Western countries, including the US, UK, and Europe.
  • Novavax's vaccine showed an efficacy rate of 90% in clinical trials, but is yet to be approved for emergency use in any country.
  • Biological E, the Indian partner of J&J, is producing doses of the J&J vaccine, while the Serum Institute of India (SII) is producing Novavax's vaccine in India.
  • SII's CEO, Adar Poonawalla, expects Covavax (Novavax's vaccine) to become available for adults by October and for children by the first quarter of next year if all regulatory processes proceed as planned.
  • The J&J vaccine has shown 66-72% efficacy in different trials, and has already been approved by regulators in several countries.

Statistics:

  • Johnson & Johnson (J&J) has applied for emergency approval of its COVID-19 vaccine in India.
  • Novavax has applied for emergency approval of its COVID-19 vaccine in India, Indonesia, and the Philippines.
  • Novavax has completed the submission of all modules required by regulatory agencies in India, Indonesia, and the Philippines for the review of its COVID-19 vaccine.
  • J&J's vaccine has been approved in several Western countries, including the US, UK, and Europe.
  • J&J's vaccine has shown 66-72% efficacy in different trials.
  • Novavax's vaccine showed an efficacy rate of 90% in clinical trials.

Sources:

  • Johnson & Johnson Pvt Ltd's statement on August 5, 2021.
  • Novavax's statement on August 5, 2021.
  • Hindustan Times.